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Abstract
Background: Matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) for yeast
identification is limited by the requirement for protein extraction and for robust reference spectra across yeast species in
databases. We evaluated its ability to identify a range of yeasts in comparison with phenotypic methods.
Methods: MALDI-TOF MS was performed on 30 reference and 167 clinical isolates followed by prospective examination of
67 clinical strains in parallel with biochemical testing (total n=264). Discordant/unreliable identifications were resolved by
sequencing of the internal transcribed spacer region of the rRNA gene cluster.
Principal Findings: Twenty (67%; 16 species), and 24 (80%) of 30 reference strains were identified to species, (spectral score
$2.0) and genus (score $1.70)-level, respectively. Of clinical isolates, 140/167 (84%) strains were correctly identified with
scores of $2.0 and 160/167 (96%) with scores of $1.70; amongst Candida spp. (n=148), correct species assignment at
scores of $2.0, and $1.70 was obtained for 86% and 96% isolates, respectively (vs. 76.4% by biochemical methods).
Prospectively, species-level identification was achieved for 79% of isolates, whilst 91% and 94% of strains yielded scores of
$1.90 and $1.70, respectively (100% isolates identified by biochemical methods). All test scores of 1.70–1.90 provided
correct species assignment despite being identified to ‘‘genus-level’’. MALDI-TOF MS identified uncommon Candida spp.,
differentiated Candida parapsilosis from C. orthopsilosis and C. metapsilosis and distinguished between C. glabrata, C.
nivariensis and C. bracarensis. Yeasts with scores of ,1.70 were rare species such as C. nivariensis (3/10 strains) and C.
bracarensis (n=1) but included 4/12 Cryptococcus neoformans. There were no misidentifications. Four novel species-specific
spectra were obtained. Protein extraction was essential for reliable results.
Conclusions: MALDI-TOF MS enabled rapid, reliable identification of clinically-important yeasts. The addition of spectra to
databases and reduction in identification scores required for species-level identification may improve its utility.
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Introduction
Yeast infections cause significant mortality in critically ill and
immunocompromised patients. In particular, Candida species are
the 4
th most common cause of nosocomial bloodstream infections
in the United States, and Cryptococcus neoformans, the commonest
cause of fungal meningitis worldwide [1,2]. Whilst Candida albicans
remains the leading pathogenic yeast, infections due to non-C.
albicans species such as Candida glabrata, as well as previously rare
opportunists such as Trichosporon and Geotrichum species, are
increasingly reported [1,3–6]. Novel pathogenic Candida species
such as Candida nivariensis and Candida bracarensis have also been
described [7]. Since many non-C. albicans Candida and non-Candida
yeasts are resistant or less susceptible to antifungal agents, rapid
accurate species identification is central to timely, effective
antifungal therapy [3–6,8,9].
Conventional phenotypic-based methods for yeast identifica-
tion, however, are slow (24–72 h), insensitive and often unable to
identify more unusual species. Various molecular techniques
including real-time PCR, DNA sequence analysis, microarray
analysis, and fluorescence in-situ hybridization provide accurate
identification [10,11] but are expensive, require substantial
specimen processing time (hours to a day) and are not easily
implemented as routine techniques in the clinical laboratory.
Matrix-assisted laser desorption ionization-time of flight mass
spectrometry (MALDI-TOF MS) has emerged as a powerful and
rapid tool for the identification of bacterial and yeast pathogens
[12–17]. Using MALDI-TOF MS, the protein spectral ‘‘finger-
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identification [18]. Previous studies have reported species
identification rates of 92–99% amongst collections of yeasts and
yeast-like organisms [14–17,19,20]. However, taken collectively,
the results may not be directly comparable since these studies have
used different approaches to assign species – from comparing
spectra from test organisms to reference spectra in MALDI-TOF
MS databases [16,20], to enhancing these databases, and in some
instances developing study-specific databases, with ‘‘in-house’’
spectral signatures [14,15]. There also is a continuing need to
extend the repository of reference spectra in MALDI-TOF MS
databases.
We therefore undertook the present study to evaluate the utility
of the MALDI Biotyper 2.0 Microflex LT spectrometer (Bruker
Daltonik GmbH; Bremen, Germany) with its current spectral
database in comparison with phenotypic-based methods for the
identification of a broad range of yeasts in a diagnostic laboratory.
The first part of the study comprised testing of reference and
clinical strains from our culture collection. The second was a
blinded prospective analysis of freshly-collected yeast isolates
recovered during routine laboratory work flow; discrepant results
between MALDI TOF MS and phenotypic methods were
resolved using sequence analysis of the fungal internal transcribed
spacer (ITS) regions [21,22]. Results obtained by preparation of
yeasts by extraction of fungal proteins and by direct application of
yeast colonies onto the MALDI TOF MS plate were also
compared.
Methods
Yeast isolates
A total of 264 yeast isolates were studied. These included 30
reference strains (26 species) obtained from the American Type
Culture Collection (ATCC; Rockville, MD) and the Centraalbur-
eau voor Schimmelcultures (CBS; Utrecht, The Netherlands)
(Table 1) and, 167 clinical isolates (26 species) from the culture
collections at the Centre for Infectious Diseases and Microbiology
Laboratory Services, Westmead Hospital; and the Department of
Microbiology, Liverpool Hospital, Sydney, Australia (Table 2).
For the second part of the study, 67 consecutive (57 Candida, and
10 non-Candida, yeasts) isolates (Table 2) isolated from a variety of
clinical specimens over a 2-month period were prospectively
identified by MALDI-TOF MS in parallel with conventional
biochemical methods. All isolates were subcultured onto Sabour-
aud’s dextrose agar (SDA; Difco Laboratories; Detroit; MI) for
48 hours at 30uC to ensure purity prior to testing.
Standard biochemical identification
All clinical isolates in the first part of the study were identified by
the API ID 32C (bioMerieux, Hazelwood, MO) or RapID Yeast
Plus systems (Remel Products, Lenexa, KS), with recommended
additional tests where appropriate [23,24]. Phenotypic identifica-
tion of isolates in the prospective study was performed using one or
more of the following tests: (i) Candida isolates - germ tube test,
appearance on CHROMagar
TM Candida (CHROMagar
TM. Paris,
France), RapID Yeast Plus or API ID 32 or Vitek 2 (bioMerieux)
identification systems; (ii) cryptococcal isolates – urease assimila-
tion, API ID 32 system, and appearance on canavanine glycine
bromothymol blue agar [25]. All other yeasts were identified by
the RapID Yeast Plus and/or API ID 32 identification systems.
DNA extraction, PCR amplification and DNA sequencing
Sequencing of the ITS 1, 5.8S rRNA and ITS 2, or the D1–D2,
regions of the 28S subunit of the rRNA gene, was performed as
required to verify species identity of reference strains (Table 1)
whilst ITS sequencing was undertaken in all cases of discrepant
identifications or ‘‘no identifications’’ obtained by MALDI-TOF
MS and phenotypic identification methods [21,26]. DNA extrac-
tion was performed using the High Pure DNA Template Prepa-
ration kit (Roche Diagnostics, Mannheim, Germany), according to
the manufacturer’s instructions.
PCR amplification of the entire ITS (ITS1, 5.8S, and ITS2)
region was performed as previously described using the primers
ITS1 and ITS4 [22]. PCR products were purified using the GFX
PCR DNA and Gel Band Purification kit (GE Healthcare UK
Limited; Little Chalfont, Buckinghamshire) and commercially
sequenced using the ITS 1 primer and the BigDye Terminator v.
3.1 cycle sequencing kit in the ABI PRISM 3100 genetic analyzer
(Applied Biosystems, Foster city, CA). Sequences were edited using
Chromas v. 2.23 software (Technelysium Pty. Ltd.) and entered
into a BLASTN search [27] provided by GenBank (http://blast.
ncbi.nlm.nih.gov/Blast.cgi) for species identification. A percent
similarity (identity) score of $98% between the unknown (query)
sequence and the database sequence of closest match was used as
the criterion to classify an isolate to species level [28].
MALDI-TOF mass spectrometry
After incubation of test strains for 48 h at 30uC on SDA, 2–3
yeast colonies were suspended in 300 mL molecular grade
deionized water and vortexed. Next, 900 mL of 100% ethanol
(Sigma-Aldrich, St Louis, MO) was then added, vortexed, and
centrifuged at 15 000 g for 2 min; the supernatant was decanted
and the centrifugation repeated once. The pellet was dried at 25uC
and reconstituted in equal volumes of 70% formic acid (Sigma-
Aldrich) and acetonitrile (Sigma-Aldrich) (in 50 mL volumes),
mixed thoroughly, followed by centrifugation (15 000 g) for 2 min.
One microliter of supernatant was spotted onto a 96-spot steel
plate (Bruker Daltonik) and allowed to dry at room temperature
before addition of 1 mL of MALDI matrix (a saturated solution of
a-cyano-4-hydroxycinnamic acid (Bruker Daltonik)). Each sample
was tested in quadruplicate to ensure reproducibility of spectra. An
Escherichia coli protein extract test standard (Bruker Daltonik) was
used to calibrate the instrument and a negative extraction control
included for each run. For a subset of clinical isolates (n=88) in
the first part of the study, the direct colony method was also used
whereby yeasts grown on SDA were applied directly as a thin film
to the steel plate and allowed to dry at room temperature before
MALDI-TOF MS analysis.
Mass spectra were generated with the Microflex LT mass
spectrometer (Bruker Daltonik GmbH) using the manufacturer’s
protocol. Briefly, <240 laser shots per sample spot were acquired
using the recommended instrument settings for organism identi-
fication (linear positive mode, 60 Hz laser frequency, 20 kV
acceleration voltage, 16.75 kV IS2 voltage, 170 ns pulsed ion
extraction delay, and 2,000 to 20,137 m/z range). Manual and
automated spectrum processing and species identification were
performed with the MALDI-Biotyper 3.0 application and software
(version 3.1.2.0; Bruker Daltonik GmbH). The software compares
acquired sample spectra to reference spectra in the provided
database and compiles a list of best matching database records.
Identification scores were interpreted according to the manufac-
turer’s recommended criteria: a score of $2.0 indicated species-
level identification, a score of 1.70–1.999 indicated identification
to the genus level, and a score of ,1.70, was interpreted as ‘‘no
reliable identification’’.
For each organism, three of four MS tests within the same
category of score were required for a definitive result. Failures (ie.
if , three tests were of the same score, or if ‘‘no reliable
Yeast Identification by MALDI-TOF MS
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was whenever the resolved final genus identification differed from
that proposed by MALDI-TOF MS while a result was a minor
error when the genus identification was concordant but the species
name was incorrect.
Results
Initial experiments on 88 archived clinical isolates showed that
extraction of yeast proteins (see Methods) was essential for
accurate MALDI-TOF MS identifications. Using the direct colony
preparation method, correct species-, and genus-level identifica-
tions were obtained for 14% and 69% of C. albicans isolates (total
tested, n=36), 35% and 74% of C. glabrata (n=23 tested) and 13%
and 38% of C. lusitaniae (n=8 tested). Analysis of the remaining
isolates inclusive of nine C. kefyr and 12 C. parapsilosis strains
produced no reliable spectra. Protein extraction of yeasts was
subsequently always performed.
Reference strains
Correct species-level identification according to the manufac-
turer’s criteria (spectral score $2.0) was obtained for 20 of 30
reference strains (16 species) including all common Candida species
- C. albicans, C. glabrata, Candida tropicalis, Candida parapsilosis and
Candida krusei [1,3]) -, C. neoformans and Cryptococcus gattii (Table 1).
One isolate each of Candida colliculosa, Candida orthopsilosis, Candida
rugosa and Pichia ohmeri was resolved to ‘‘genus-level’’ ie. score of
.1.70 (but ,2.0) yet yielded the correct final species designation.
MALDI-TOF MS distinguished between C. parapsilosis, Candida
Table 1. MALDI TOF MS identification of 30 reference yeast strains.
Isolates MALDI-TOF Identification according to Bruker Score
*
,1.70 $1.7-,2.0 $2.0
Candida spp.
Candida albicans CBS 562 C. albicans
Candida albicans ATCC 10231 C. albicans
Candida catenulata CBS 565 C. catenulata
Candida ciferii CBS 4856# No ID (Candida orthopsilosis)
Candida colliculosa CBS 133 C. colliculosa
Candida dubliniensis CBS 7987 C. dubliniensis
Candida glabrata ATCC 90030 C. glabrata
Candida guilliermondii CBS 2030 C. guilliermondii
Candida haemulonii CBS 5149 C. haemulonii
Candida kefyr ATCC 4135 C. kefyr
Candida krusei ATCC 6258 C. krusei
Candida lipolytica CBS 6124 C. lipolytica
Candida lusitanae CBS 5030 C. lusitanae
Candida metapsilosis ATCC 96144 C. metapsilosis
Candida norvegensis CBS 1922 C. norvegensis
C. orthopsilosis ATCC 96139 C. orthopsilosis
Candida parapsilosis CBS 604 C. parapsilosis
Candida parapsilosis ATCC 22019 C. parapsilosis
Candida rugosa CBS 613 C. rugosa
Candida tropicalis CBS 94 C. tropicalis
Candida utilis CBS 1600 C. utilis
Candida utilis ATCC 9950 C. utilis
Candida zeylanloides CBS 619 No ID (C. zeylanoides)
Other yeasts
Arxiozyma telluris1 CBS 2685 No ID (Candida sloofii1)
Arxiozyma telluris CBS 2676 No ID (C. krusei)
Cryptococcus neoformans ATCC 00112 C. neoformans
Cryptococcus gattii" ATCC 32608 Filobasidiella bacillisporus"
Debaryomyces carsonii CBS 2285# No ID (C. neoformans)
Pichia kluyveri CBS 3082# No ID(C. krusei)
Pichia ohmeri CBS 5367 P. ohmeri
ID, identification; species designated within brackets refers to closest match species.
*Results from testing of four replicates.
#Reference species-specific spectra not contained in software (version 3.1.2.0, Bruker Daltonik GmbH).
"A. telluris synonymous with C. sloofii; C. gattii synonymous with F. bacillisporus.
doi:10.1371/journal.pone.0025712.t001
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to ‘‘genus-level’’ (Table 1).
There were no minor errors and no misidentifications (major
errors). However, five species (n=6 isolates) produced spectral
scores ,1.70 with ‘‘no reliable identification’’. Species which
provided the closest spectral-based match for these isolates are
shown in Table 1. Reference spectra for three species, Candida
ciferii, Pichia kluyveri and Debaromyces carsonii, were not present in the
Biotyper software. The remaining two species (Arxiozyma telluris,
Candida zeylanoides) failed to match their respective species-specific
reference spectra. However, for A. telluris CBS 2685 (Table 1), the
closest spectral match identified the strain as Candida sloofii; both A.
telluris and C. sloofii are species reduced to synonymy [29].
Overall, measured against current reference spectra in the
Biotyper version 3.1.2.0 library (Bruker Daltonik GmbH),
concordance with DNA sequence analysis in identification to
species-, and genus-level was 67% (20/30 isolates) and 80% (24/
30 isolates), respectively. For species included in the database,
Table 2. Species and genus identification of clinical yeast isolates by MALDI-TOF MS.
Yeast species
(final ID)* No. tested
No ID
(score ,1.7)
No. with genus
level ID (score $1.7)
% genus
ID
No. with species
level ID (score .2.0)
% species
ID
Retrospective study
Candida spp. 148 6 142 96 127 86
Candida albicans 25 0 25 100 25 100
Candida bracarensis 11 0 0 0 0
Candida dubliniensis 6 0 6 100 3 50
Candida famata 2 0 2 100 2 100
Candida glabrata 27 0 27 100 25 93
Candida guilliermondii 11 1 10 91 9 82
Candida haemulonii 1 0 1 100 1 100
Candida krusei 10 0 10 100 10 100
Candida lusitaniae 12 0 12 100 10 83
Candida nivariensis 10 3 7 70 5 50
Candida orthopsilosis 1 0 1 100 1 100
Candida parapsilosis 17 1 16 94 15 88
Candida sphaerica 1 0 1 100 1 100
Candida tropicalis 14 0 14 100 14 100
Candida utilis 10 0 10 100 6 60
Non-Candida yeasts 19 1 18 95 13 68
Arxiozyma telluris 11 0 0 0 0
Cryptococcus gattii 10 1 1 0 0 0 0
Cryptococcus neoformans 5 0 5 100 2 40
Geotrichum candidum 1 0 1 100 1 100
Geotrichum silvicola 1 0 1 100 1 100
Lipomyces orientalis 9 0 9 100 8 89
Lodderomyces elongisporus 1 0 1 100 1 100
Prospective study
C. albicans 18 0 18 100 17 94
Candida catenulata 1 0 1 100 1 100
C. dubliniensis 2 0 2 100 2 100
C. glabrata 26 0 26 100 22 85
C. kefyr 10 1 1 0 0 0 0
C. parapsilosis 7 0 7 100 6 86
C. tropicalis 1 0 1 100 1 100
C. krusei 1 0 1 100 1 100
C. neoformans 64 2 3 3 1 1 7
C. gattii 1 0 1 100 1 100
Geotrichum capitatum 1 0 1 100 1 100
Rhodotorula mucilaginosa 10 1 1 0 0 0 0
Saccharomyces cerevisiae 10 1 1 0 0 0 0
*All discrepant identifications between MALDI-TOF MS and biochemical methods were resolved by ITS sequencing [21,22].
doi:10.1371/journal.pone.0025712.t002
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Clinical isolates: Retrospective study
(i) MALDI-TOF MS identifications. One hundred and
forty of 167 archived isolates (84%) yielded spectra which fulfilled
the criteria for species-level identification, and 160 (96%) isolates,
for genus-level identification (Table 2). Collectively, Candida
pathogens yielded a higher percentage of spectral scores of #2.0
(127 isolates; 86%) than non-Candida yeasts (68%).
The mean best (ie. closest)-match score values for Candida
species in general, showed little intra-species variation. Table 3
summarises these data for the major Candida species (all with mean
score values of $2.0). C. nivariensis had a lower mean score value
(1.81+/20.31; Table 3). Amongst Candida isolates, four Candida
utilis, three Candida dubliniensis, two C. glabrata, two Candida lusitaniae,
two C. nivariensis, and a single isolate each of Candida gulliermondii
and C. parapsilosis had spectral scores of 1.7–2.0 yet the resolved
species identification was correct. Thus, 142/148 or 96% of
isolates were resolved to correct species at a score of $1.7. For
non-Candida yeasts, MALDI-TOF MS enabled correct identifica-
tion of Cryptococcus spp. and other yeasts including Geotrichum and
Lodderomyces elongisporus. Five of 19 (26.3%) isolates including four
Cryptococcus isolates were resolved to the correct species but with
scores of 1.72–1.79 (Table 2).
(ii) MALDI-TOF MS versus conventional identifi-
cation. For Candida spp., MALDI-TOF MS and phenotypic-
based identification provided correct species-level identification for
127 (85.8%) and 112 (75.6%) isolates, respectively (data not shown).
Of 17 discordant identifications, 16 were resolved in favour of
MALDI-TOF MS using ITS sequencing. The MALDI Biotyper was
able to identify C. nivarineisis (n=5 isolates), Candida famata (n=2), C.
lusitaniae (n=2) and Candida haemulonii (n=1), with scores of $2.0,
where biochemical methods yielded a result of ‘‘Candida spp.’’
Biochemical methods also erroneously classified three strains of C.
parapsilosis as C. lusitaniae, and a single strain each of C. guilliermondii, C.
glabrata and Candida sphaerica as other Candidaspecies.Conversely,they
identified a C. parapsilosis isolate that yielded no identification by
MALDI-TOF.
Concordance with biochemical identification to genus level was
present for 26/27 (97%) for non-Candida isolates (data not shown).
Phenotypic methods were unable to identify Geotrichum candidum,
Geotrichum silvicola and L. elongisporus, all successfully identified by
MALDI-TOF MS, yet speciated all six Cryptococcus spp., of which
only two yielded spectral scores of .2.0.
(iii) Incorrect and no identification. There were no major
errors by MALDI-TOF MS. Six isolates (3.6%) yielded a result of
‘‘no identification’’ (score of,1.7). These were three C. nivariensis,
one C. bracarensis, one C. guilliermondii and one A. telluris isolates
(Table 2). Reference spectra for C. bracarensis are not present in the
Bruker database version 3.2.1.0 (Bruker Daltonik).
Clinical isolates: Prospective study
Table 2 summarises the identification results for 67 yeast isolates
(13 species) by conventional methods, MALDI-TOF MS and the
final species designation as determined by ITS sequencing.
Biochemical methods identified all 67 isolates. There were no
major errors in identification by MALDI-TOF MS.
Four of the six cryptococcal isolates studied were not identified
by MALDI-TOF MS criteria (scores 1.3–1.5; Table 2). Assign-
ment to species level at a score of $2.0 was achieved for 53 (79%)
isolates (100% concordant with biochemical identification meth-
ods). Ten isolates including four C. glabrata, one C. albicans and one
C. parapsilosis, had spectral scores of .1.70 but ,2.0; single isolates
of Candida kefyr (mean score 1.93), Rhodotorula mucilaginosa (mean
score 1.96) and Saccharomyces cerevisiae (mean score 1.97) also yielded
similar spectral scores (Table 2). All genus-level identifications
resolved isolates to their correct species designations.
The time to issuing a definitive identification result by
phenotypic tests after recovery of the isolate on culture was 24–
72 h whilst the average hands-on time per isolate for MALDI-
TOF MS identification after culture isolation was approximately
one hour including sample preparation.
Discussion
Whilst the utility of the MALDI-TOF MS is established for the
efficient, routine identification of bacteria [12,30], its position in
assisting with, or replacing, phenotypic identification of yeasts in
the clinical mycology laboratory is less well defined. The present
study re-affirms and extends the results of previous reports of the
ability of the Bruker Microflex LT (Bruker Daltonik) MALDI-
TOF system to provide fast and accurate identification of a broad
range of yeasts. Key findings were that (a) identification was genus-
as well as species- dependent, (b) there were no major errors,
including in the absence of reference spectra for a species, resulting
in misidentifications, and (c) isolates with spectral scores between
1.70 and 1.90 were all correctly resolved.
We first validated MALDI-TOF MS for yeast identification
using well-characterised reference strains in comparison with ITS
sequencing. To more accurately represent the utility of the
MALDI Biotyper 2.0 instrument with its current database, we did
not add new spectral entries to the database. Although not all
isolates achieved species-level identification using manufacturer-
recommended criteria, all common Candida species [1,3] were
unambiguously assigned (Table 1). Uncommon Candida spp. with
genus-level identifications were also resolved to their correct
species and importantly, ‘‘misidentifications’’ only associated with
scores of ,1.70 and therefore not given an identification. Whilst
we cannot explain why C. zeylanoides CBS 619 (spectra contained in
the Bruker library version 3.1.2.1), was not identified, lower scores
may result from poor extraction technique, inadequate drying of
the yeast pellet or inadvertent inclusion of agar into the extract.
However, the scores were reproducible between runs and high
scores ($2.0) were achieved for common yeasts (Tables 1, 2, 3)
analysed within the same run using identical protein extraction.
Lower scores for uncommon yeasts have been noted by others
[14–16]. The ability to provide species-level identification is
dependent on the number of entries per species in the
manufacturer’s database, usually being higher for common
isolates. A higher number of entries for the same species (as for
Table 3. Variations of the match score values generated by
the Biotyper system for selected Candida species.
Isolate
No. of isolates (tested
in quadruplicate) Mean +/2 SD
Candida albicans 25 2.26+/20.09
Candida glabrata 27 2.20+/20.13
Canddia krusei 10 2.18+/20.07
Candida nivariensis 10 1.81+/20.31
Candida parapsilosis 17 2.19+/20.13
Candida tropicalis 14 2.19+/20.10
Abbreviations: SD, standard deviation.
doi:10.1371/journal.pone.0025712.t003
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to possible variation in protein expression between strains [31];
such intraspecies variation in fungi which may impact on protein
spectral profiles warrants further study.
Examination of a large number of clinical strains (n=167)
confirmed the observations for reference strains. When measured
against ITS sequence analysis, MALDI-TOF MS performed
better than biochemical tests (84% of isolates correctly identified
with spectral scores of $2.0 vs. 76.4%). Other studies examining
yeast profiles following protein extraction have noted that lowering
the score threshold for species-level identification to $1.80 or even
$1.70 can still be used to provide reliable identification [14,16]. In
our study, a score cut off of $1.70 allowed correct identification of
96% of isolates, and Candida isolates, lowering the threshold from
$2.0 to $1.70 increased species-level identification by an
additional 12%. Despite these findings, however, analyses of large
numbers of different yeast species across multiple centres using
standardised extraction methods are essential prior to defining a
consensus cut-off score. Mean score values for common Candida
species (eg. C. albicans, C. glabrata) were $2.0 with small standard
deviations reflecting good result reproducibility, and likely, the
number of spectra from these species already contained in the
database. C. nivariensis yielded lower mean score values with
greater variance (1.81+/20.31); reproducibility is likely to
improve with additions of reference spectra into the database
(currently, n=2 in the database). Five species of non-Candida yeasts
were profiled with scores of $2.0 yet four of six Cryptococcus strains
had scores of ,2.0 ($1.70; see below).
The Bruker database (version 3.1.2.1) used in our study was a
more recent version containing a larger number of spectral entries
compared with that in three other studies [14–16] and logically,
may be expected to provide better identification rates. Possible
explanations for the apparent reduced ability of MALDI-TOF MS
to identify isolates to ‘‘species level (84%) in comparison with
previous reports (87–100%) include differences in the range or mix
of yeast species, and nature of the database employed. In studies
where complementation of the manufacturer’s database with in-
house spectra or where the reference database was specifically
constructed for the purpose of the study, species-level identification
rates have ranged from 92.5–100% [14,15,32]. Others using the
Bruker database without supplementation have reported similar
identification rates to those observed herein [16,20].
A novel finding was the ability of MALDI-TOF MS to
distinguish within the C. glabrata clade ie. between C. glabrata and
C. nivariensis and C. bracarensis, which presently rely on molecular
methods for species separation [7,33,34]. Spectra from C. nivariensis
were clearly distinguished from those of C. glabrata. Seven of 10
clinical isolates had spectral scores of .1.8 (five were .2.0;
Table 2); possible reasons for the lower scores for the remaining
three include suboptimal protein extraction despite every care with
the manufacturer’s extraction protocol, or variability in protein
expression within this species. Spectra from the only isolate of C.
bracarensis were novel. Members of the C. parapsilosis species
complex, indistinguishable by biochemical methods [35], were also
resolved by MALDI-TOF MS, including C. parapsilosis sensu stricto,
C. metapsilosis and C. orthopsilosis [14,15,17]. Quiles-Melero et al
reported that these three species as assigned by pyrosequencing,
yielded MALDI-TOF MS results with 100% concordance [36].
We noted that a further member of the C. parapsilosis group, L.
elongisporus, also yielded species-level identification. Differentiation
of species within the C. parapsilosis and C. glabrata complexes is
important since there are species-specific differences in antifungal
susceptibilities and ability to form biofilms in vitro [34,35,37].
We further assessed in real time the efficiency of MALDI-TOF
MS for routine yeast identification. Although only 79% of yeasts
achieved species-level identification, all genus-level identification
results (94%) yielded the correct final species designation. There
were no major errors. Biochemical methods provided 100%
species identification in this arm of the study as they identified four
C. neoformans isolates that produced a score of ,1.70 by MALDI-
TOF (the ‘‘closest match’’ spectra still assigned the correct species).
Unreliable identifications for C. neoformans have been reported by
others (identification rates 50–66%) [14,16] and may be due to the
polysaccharide capsule of this pathogen, rendering extraction and
solubilisation of proteins difficult or due to insufficient database
entries to enable spectral matches. We observed for Cryptococcus
spp., that colonies with mucoid morphology posed technical
difficulties with extraction, often requiring repeat analysis.
Although McTaggart et al. reported species-level identification
rates of 100% for Cryptococcus spp. [32] this was only after
complementation of Bruker software with home-generated
spectra.
The results of the present study have also provided novel spectra
for four pathogens - C. ciferi, C. bracarensis, P. kluyveri, and D. carsonii
- for future integration into the Bruker library. Spectra were
acquired by testing each isolate in quadruplicate to ensure good
reproducibility and on two separate occasions (data not shown) but
require further independent validation by testing larger numbers
of isolates.
Preparation for MALDI-TOF MS analysis can be undertaken
in two ways. Although the direct colony method is used to identify
bacteria, our attempts to adapt this for yeasts resulted in no spectra
or unacceptably low scoring spectra in a large proportion of cases
including for the most common pathogen, C. albicans, and there is
now evidence that even for bacteria, extraction methods may be
necessary [38]. By adhering to the manufacturer’s protocol for
fungal cell wall disruption, reliable spectra were achieved in most
instances. Other clues in assessing MALDI-TOF results include
noting that the highest scores for species-level identification were
seen when there was a large gap in score values or ‘‘score jump’’
between the most likely identification to the next most likely result
([39], this study).
MALDI-TOF MS offers considerable savings in time and cost
over standard yeast identification methods. A single isolate may be
identified in 45–60 mins including extraction time; up to 96
isolates may be identified within 3 h at AUD0.50 per sample and
the protein extraction procedure is readily integrated into routine
workflow. Phenotypic identification methods cost < AUD10 per
sample and take up to 48 h for definitive results. Costs associated
with ITS sequencing where phenotypic methods cannot provide
identification are <AUD9 per isolate (turn-around-time 48 h).
The limitations of MALDI-TOF MS, however, are acknowledged.
Robust reference spectra are required with regular curation. Other
limitations are the high capital costs (<AUD 250000) and inability
to detect mixed cultures.
In conclusion, the rapid, accurate identification of pathogenic
yeasts by MALDI-TOF MS is contingent on optimal protein
extraction and upon robust reference spectra. Candida species were
reliably identified, with superior performance of MALDI-TOF
MS over conventional methods. However, MALDI-TOF MS was
less reliable in distinguishing between C. neoformans and C. gattii
compared with biochemical methods.
Acknowlegdments
We thank Mr. Leith Fremlin (Bruker Daltonik, Australia) for helpful
technical advice and Ms. Sue Sleiman for assistance with phenotypic isolate
identifications.
Yeast Identification by MALDI-TOF MS
PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e25712Author Contributions
Conceived and designed the experiments: AP SC-AC SvH WM JRI TO.
Performed the experiments: AP CH MZ KM. Analyzed the data: AP SC-
AC CH SvH JRI. Contributed reagents/materials/analysis tools: AP SC-
AC KM CH SvH MZ TO. Wrote the paper: AP SC-AC CH SvH. Editing
and approval of final version of manuscript: AP CH MZ SvH KM TO JRI
WM SC-AC.
References
1. Pfaller MA, Diekema DJ (2010) Epidemiology of invasive mycoses in North
America. Crit Rev Microbiol 36: 1–53.
2. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, et al. (2009)
Estimation of the current global burden of cryptococcal meningitis among
persons living with HIV/AIDS. AIDS 23: 525–530.
3. Chen S, Marriott D, Playford G, Nguyen Q, Ellis D, et al. (2009) Candidaemia
with uncommon Candida species: predisposing factors, outcome, antifungal
susceptibility, and implications for management. Clin Microbiol Infect 15:
662–669.
4. Girmenia C, Pagano L, Martino B, D’Antonio D, Fanci R, et al. (2005) Invasive
infections caused by Trichosporon species and Geotrichum capitatum in patients with
haematological malignancies: a retrospective multicentre study from Italy and
review of the literature. J Clin Microbiol 43: 1818–1828.
5. Atkinson BJ, Lewis RE, Kontoyiannis DP (2008) Candida lusitaniae fungaemia in
cancer patients: risk factors for amphotericin B failure and outcome. Med Mycol
46: 541–546.
6. Ruan SY, Chien JY, Hsueh PR (2009) Invasive trichosporonosis caused by
Trichosporon asahii and other unusual Trichosporon species at a medical centre in
Taiwan. Clin Infect Dis 49: 11–17.
7. Cuenca-Estrella M, Gomez-Lopez A, Isla G, Rodriguez D, Almirante B, et al.
(2011) Prevalence of Candida bracarensis and Candida nivariensis in a Spanish
collection of yeasts: comparison of results from a reference centre and from a
population-based surveillance study of candidemia. Med Mycol 49: 525–9.
8. Hsu DL, Nguyen M, Nguyen L, Law A, Wong-Beringer A (2010) A multicentre
study to evaluate the impact of timing of caspofungin administration on
outcomes of invasive candidiasis in non-immunocompromized adult patients.
J Antimicrob Chemother 65: 1765–70.
9. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, et al. (2006) Time to
initiation of fluconazole therapy impacts mortality in patients with candidemia: a
multi-institutional study. Clin Infect Dis 43: 25–31.
10. Lau A, Chen SCA, Sleiman S, Sorrell TC (2009) Current Status and Future
Perspectives on Molecular and Serological Methods in Diagnostic Mycology.
Future Microbiol 4: 1185–1222.
11. Shepard JR, Addison RM, Alexander BD, Della-Latta P, Gherna M, et al.
(2008) Multicentre evaluation of the Candida albicans/Candida glabrata peptide
nucleic acid fluorescent in situ hybridisation method for simultaneous dual-
colour identification of C. albicans and C. glabrata directly from blood culture
bottles. J Clin Microbiol 46: 50–55.
12. Eigner U, Holdelder M, Oberdorfer K, Betz-Wild U, Bertsch D, et al. (2009)
Performance of a matrix-assisted laser desorption ionization time-of flight mass
spectrometry system for the identification of bacterial isolates in the clinical
routine laboratory. Clin Lab 55: 289–296.
13. Sauer S, Kliem M (2010) Mass spectrometry tools for the classification and
identification of bacteria. Nat Rev Microbiol 8: 74–82.
14. Stevenson L, Drake S, Shea Y, Zelazny A, Murray P (2010) Evaluation of
matrix-assisted laser desorption ionization-time of flight mass spectrometry for
identification of clinically important yeast species. J Clin Microbiol 48:
3482–3486.
15. Marklein G, Josten M, Klanke U, Muller E, Horre R, et al. (2009) Matrix-
assisted laser desorption ionization time of flight mass spectrometry for fast and
reliable identification of Clinical Yeast Isolates. J Clin Microbiol 47: 2912–2917.
16. Dhiman N, Hall L, Wohfiel SL, Buckwalter SP, Wengenack N L (2011)
Performance and cost analysis of MALDI-TOF mass spectrometry for routine
identification of yeast. J Clin Microbiol. Available: doi: 10.1128/JCM.02381-10.
Accessed 2011 Jul 20.
17. Bader O, Weig M, Taverne-Ghadwal L, Lugert R, Groß U, et al. (2010)
Improved clinical laboratory identification of human pathogenic yeasts by
matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clin
Microbial Infect. Available: doi: 10.1111/j.1469-0691.2010.03398.x. Accessed
2011 Jun 01.
18. Saffert RT, Cunningham SA, Ihde SM, Monson Jobe KJE, Mandrekar J, et al.
(2011) Comparison of Bruker Biotyper MALDI-TOF mass spectrometer to BD
Phoenix automated microbiology system for identification of gram negative
bacilli. J Clin Microbiol 49: 887–892.
19. Ferroni A, Suarez S, Beretti JL, Daophin B, Bille E, et al. (2010) Real-time
identification of bacteria and Candida species in positive blood culture broths by
matrix-assisted laser desorption ionization-time of flight mass spectrometry.
J Clin Microbiol 48: 1542–1548.
20. van Veen SQ, Claas ECJ, Kujiper EJ (2010) High throughput identification of
bacteria and yeast by matrix-assisted laser desorption ionization-time of flight
mass spectrometry in conventional medical microbiology laboratories. J Clin
Microbiol 48: 900–907.
21. Leaw SN, Chang HC, Sun HF, Barton R, Bouchara JP, et al. (2006)
Identification of medically important yeast species by sequence analysis of the
internal transcribed spacer regions. J Clin Microbiol 44: 693–699.
22. White TJ, Burns T, Lee S, Taylor JW (1990) Amplification and direct
sequencing of fungal ribosomal RNA genes for phylogenetics. In: Innis MA,
Gelfand DH, Sninsky JJ, White TJ, eds. PCR Protocols: A Guide to Methods
and Applications. New York: Academic Press, Inc. pp 315–322.
23. Hazen KC, Howell SA (2007) Candida, Cryptococcus, and other yeasts of medical
importance. In: Murray PR, Barron EJ, Jorgensen JH, Landry ML, Pfaller MA,
eds. Manual of Clinical Microbiology. HerndonVA: ASM Press. pp 1762–1788.
24. Kurtzman CP, Fell JW (1998) The Yeasts, A Taxonomic study. 4
th Edition. B.V.
Amsterdam, The Netherlands: Elsevier Science. pp 77–99.
25. Kwon-Chung KJ, Polacheck I, Bennett JE (1982) Improved diagnostic medium
for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and
Cryptococcus neoformans var. gattii (serotypes B and C). J Clin Microbiol 15: 535–7.
26. Ciardo DE, Schar G, Bottger EC, Altwegg M, Bosshard PP (2006) Internal
transcribed spacer sequencing versus biochemical profiling for identification of
medically important yeasts. J Clin Microbiol 44: 77–84.
27. Altschul SF, Madden TL, Scha ¨ffer AA, Zhang J, Zhang Z, et al. (1997) Gapped
BLAST and PSI-BLAST: a new generation of protein database search
programs. Nucleic Acids Res 25: 3389–3402.
28. Petti CA, Bosshard PP, Brandt ME, Clarridge JE, Feldblyum TV, et al. (2008)
Interpretive Criteria for Identification of Bacteria and Fungi by DNA Target
Sequencing; Approved Guideline. In: Clinical and Laboratory Standards
Institute MM18-A. Wayne, PA. pp 54–59.
29. James SA, Collins MD, Roberts IN (2001) Phylogenetic analysis of the
psychrophobic yeast Arxiozyma telluris and the reinstatement of Candida pintolopesii
(van Uden) Meyer et Yarrow and Candida slooffii van Uden et doCarmo Sousa.
Int J of Syst and Evol Microbiol 51: 1917–1925.
30. Carbonelle E, Mesquita C, Bille E, Day N, Duaphin B, et al. (2011) MALDI-
TOF mass spectrometry tools for bacterial identification in clinical microbiology
laboratory. Clinical Biochem 44: 104–109.
31. Lartigue MF, Gery-Arnaud G, Haguenoer E, Domelier AS, Schmit PO, et al.
(2009) Identification of Streptococcus agalactiae isolates from various phylogenetic
lineages by matrix-assisted laser desorption ionization-time of flight mass
spectrometry. J Clin Micrbiol 47: 2284–2397.
32. McTaggart L, Lei E, Richardson SE, Hoang L, Fothergill A, et al. (2011) Rapid
identification of Cryptococcus neoformans and Cryptococcus gattii by matrix assisted
laser desorption ionization-time-of-flight mass spectrometry (MALDI-TOF MS).
J Clin Microbiol 2011; 49: 3050–3053.
33. Correia A, Sampaio P, James S, Pais C (2006) Candida bracarensis sp. nov., a novel
anamorphic yeast species phenotypically similar to Candida glabrata. Int J Syst
Evol Microbiol 56: 313–317.
34. Borman AM, Petch R, Linton CJ, Palmer MD, Bridge PD, et al. (2008) Candida
nivariensis, an emerging pathogenic fungus with multidrug resistance to antifungal
agents. J Clin Microbiol 46: 933–938.
35. Tavanti A, Davidson AD, Gow NAR, Maiden MCJ, Odds FC (2005) Candida
orthopsilosis and Candida metapsilosis spp. nov. To Replace Candida parapsilosis
Groups II and III. J Clin Microbiol 43: 284–292.
36. Quiles-Melero I, Garcia-Rodriguez J, Gomez-Lopez A, Mingorance J (2011)
Evaluation of matrix-assisted laser desorption.ionisation time-of-flight (MALDI-
TOF) mass spectrometry for identification of Candida parapsilosis, C. orthopsilosis
and C. metapsilosis. Eur J Clin Microbiol Infect Dis. doi: 10.1007/s10096-011-
1277-z.
37. van Asbeck E, Clemons RV, Martinez M, Tong AJ, Stevens DA (2008)
Significant differences in drug susceptibility among species in the Candida
parapasilosis group. Diagn Microbiol Infect Dis 62: 106–109.
38. Alatoom A, Cunningham S, Ihde S, Mandrekar J, Patel R (2011) Comparison of
Identification of Gram Positive Cocci Using Direct Colony versus Extraction
Methods by Bruker Biotyper MALDI-TOF Mass Spectrometry. J Clin
Microbiol. Available: doi:10.1128/JCM.00506-11. Accessed 2011 Jul 20.
39. Iranzo Tatay A, Frasquet Artes J, Fagundez Machiain G, Gobernado Serrano M
(2011) MALDI-TOF assay in diagnosis of fungal infections. 21st ECCMID and
27th ICC Abstract No 750. Available: http://onlinelibrary.wiley.com/doi/10.
1111/j.1469-0691.2011.03558.x/pdf. Accessed: 2011 Jul 20.
Yeast Identification by MALDI-TOF MS
PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e25712